Ultragenyx Pharmaceutical (RARE) Competitors

$25.80 -0.66 (-2.49%)

Closing price 04:00 PM Eastern

Extended Trading

$25.73 -0.07 (-0.27%)

As of 04:51 PM Eastern

RARE vs. ABVX, PRAX, PCVX, CYTK, and KRYS

Should you buy Ultragenyx Pharmaceutical stock or one of its competitors? MarketBeat compares Ultragenyx Pharmaceutical with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Ultragenyx Pharmaceutical include Abivax (ABVX), Praxis Precision Medicines (PRAX), Vaxcyte (PCVX), Cytokinetics (CYTK), and Krystal Biotech (KRYS). These companies are all part of the "pharmaceutical products" industry.

How does Ultragenyx Pharmaceutical compare to Abivax?

Abivax (NASDAQ:ABVX) and Ultragenyx Pharmaceutical (NASDAQ:RARE) are both mid-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, risk, analyst recommendations, media sentiment, earnings, valuation, profitability and institutional ownership.

47.9% of Abivax shares are held by institutional investors. Comparatively, 97.7% of Ultragenyx Pharmaceutical shares are held by institutional investors. 5.2% of Ultragenyx Pharmaceutical shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

In the previous week, Ultragenyx Pharmaceutical had 17 more articles in the media than Abivax. MarketBeat recorded 22 mentions for Ultragenyx Pharmaceutical and 5 mentions for Abivax. Abivax's average media sentiment score of 1.14 beat Ultragenyx Pharmaceutical's score of 0.09 indicating that Abivax is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Abivax	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Ultragenyx Pharmaceutical	6 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral

Abivax has a beta of 0.84, suggesting that its share price is 16% less volatile than the broader market. Comparatively, Ultragenyx Pharmaceutical has a beta of 0.39, suggesting that its share price is 61% less volatile than the broader market.

Abivax has a net margin of 0.00% compared to Ultragenyx Pharmaceutical's net margin of -91.03%. Abivax's return on equity of -146.43% beat Ultragenyx Pharmaceutical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Abivax	N/A	-146.43%	-88.69%
Ultragenyx Pharmaceutical	-91.03%	-1,024.42%	-45.78%

Abivax presently has a consensus price target of $137.15, suggesting a potential upside of 13.35%. Ultragenyx Pharmaceutical has a consensus price target of $60.41, suggesting a potential upside of 134.15%. Given Ultragenyx Pharmaceutical's higher probable upside, analysts clearly believe Ultragenyx Pharmaceutical is more favorable than Abivax.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Abivax	1 Sell rating(s)	0 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.93
Ultragenyx Pharmaceutical	1 Sell rating(s)	2 Hold rating(s)	14 Buy rating(s)	1 Strong Buy rating(s)	2.83

Abivax has higher earnings, but lower revenue than Ultragenyx Pharmaceutical. Abivax is trading at a lower price-to-earnings ratio than Ultragenyx Pharmaceutical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Abivax	N/A	N/A	-$380.27M	-$5.37	N/A
Ultragenyx Pharmaceutical	$670M	3.79	-$575M	-$6.11	N/A

Summary

Ultragenyx Pharmaceutical beats Abivax on 8 of the 15 factors compared between the two stocks.

How does Ultragenyx Pharmaceutical compare to Praxis Precision Medicines?

Ultragenyx Pharmaceutical (NASDAQ:RARE) and Praxis Precision Medicines (NASDAQ:PRAX) are both mid-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their risk, analyst recommendations, valuation, profitability, media sentiment, dividends, institutional ownership and earnings.

Praxis Precision Medicines has a net margin of 0.00% compared to Ultragenyx Pharmaceutical's net margin of -91.03%. Praxis Precision Medicines' return on equity of -43.02% beat Ultragenyx Pharmaceutical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ultragenyx Pharmaceutical	-91.03%	-1,024.42%	-45.78%
Praxis Precision Medicines	N/A	-43.02%	-40.22%

97.7% of Ultragenyx Pharmaceutical shares are owned by institutional investors. Comparatively, 67.8% of Praxis Precision Medicines shares are owned by institutional investors. 5.2% of Ultragenyx Pharmaceutical shares are owned by company insiders. Comparatively, 2.7% of Praxis Precision Medicines shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Ultragenyx Pharmaceutical has a beta of 0.39, indicating that its stock price is 61% less volatile than the broader market. Comparatively, Praxis Precision Medicines has a beta of 2.76, indicating that its stock price is 176% more volatile than the broader market.

Ultragenyx Pharmaceutical currently has a consensus price target of $60.41, suggesting a potential upside of 134.15%. Praxis Precision Medicines has a consensus price target of $592.67, suggesting a potential upside of 71.53%. Given Ultragenyx Pharmaceutical's higher probable upside, equities research analysts clearly believe Ultragenyx Pharmaceutical is more favorable than Praxis Precision Medicines.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ultragenyx Pharmaceutical	1 Sell rating(s)	2 Hold rating(s)	14 Buy rating(s)	1 Strong Buy rating(s)	2.83
Praxis Precision Medicines	2 Sell rating(s)	1 Hold rating(s)	13 Buy rating(s)	4 Strong Buy rating(s)	2.95

Praxis Precision Medicines has lower revenue, but higher earnings than Ultragenyx Pharmaceutical. Praxis Precision Medicines is trading at a lower price-to-earnings ratio than Ultragenyx Pharmaceutical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ultragenyx Pharmaceutical	$670M	3.79	-$575M	-$6.11	N/A
Praxis Precision Medicines	N/A	N/A	-$303.27M	-$13.37	N/A

In the previous week, Praxis Precision Medicines had 12 more articles in the media than Ultragenyx Pharmaceutical. MarketBeat recorded 34 mentions for Praxis Precision Medicines and 22 mentions for Ultragenyx Pharmaceutical. Praxis Precision Medicines' average media sentiment score of 0.32 beat Ultragenyx Pharmaceutical's score of 0.09 indicating that Praxis Precision Medicines is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Ultragenyx Pharmaceutical	6 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral
Praxis Precision Medicines	5 Very Positive mention(s)	6 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

Summary

Praxis Precision Medicines beats Ultragenyx Pharmaceutical on 9 of the 16 factors compared between the two stocks.

How does Ultragenyx Pharmaceutical compare to Vaxcyte?

Ultragenyx Pharmaceutical (NASDAQ:RARE) and Vaxcyte (NASDAQ:PCVX) are both mid-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their risk, analyst recommendations, valuation, profitability, media sentiment, dividends, institutional ownership and earnings.

Vaxcyte has a net margin of 0.00% compared to Ultragenyx Pharmaceutical's net margin of -91.03%. Vaxcyte's return on equity of -32.51% beat Ultragenyx Pharmaceutical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ultragenyx Pharmaceutical	-91.03%	-1,024.42%	-45.78%
Vaxcyte	N/A	-32.51%	-29.51%

97.7% of Ultragenyx Pharmaceutical shares are owned by institutional investors. Comparatively, 96.8% of Vaxcyte shares are owned by institutional investors. 5.2% of Ultragenyx Pharmaceutical shares are owned by company insiders. Comparatively, 3.1% of Vaxcyte shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Ultragenyx Pharmaceutical has a beta of 0.39, indicating that its stock price is 61% less volatile than the broader market. Comparatively, Vaxcyte has a beta of 1.3, indicating that its stock price is 30% more volatile than the broader market.

Ultragenyx Pharmaceutical currently has a consensus price target of $60.41, suggesting a potential upside of 134.15%. Vaxcyte has a consensus price target of $86.00, suggesting a potential upside of 60.66%. Given Ultragenyx Pharmaceutical's stronger consensus rating and higher probable upside, equities research analysts clearly believe Ultragenyx Pharmaceutical is more favorable than Vaxcyte.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ultragenyx Pharmaceutical	1 Sell rating(s)	2 Hold rating(s)	14 Buy rating(s)	1 Strong Buy rating(s)	2.83
Vaxcyte	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63

Ultragenyx Pharmaceutical has higher revenue and earnings than Vaxcyte. Vaxcyte is trading at a lower price-to-earnings ratio than Ultragenyx Pharmaceutical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ultragenyx Pharmaceutical	$670M	3.79	-$575M	-$6.11	N/A
Vaxcyte	N/A	N/A	-$766.63M	-$6.88	N/A

In the previous week, Ultragenyx Pharmaceutical had 16 more articles in the media than Vaxcyte. MarketBeat recorded 22 mentions for Ultragenyx Pharmaceutical and 6 mentions for Vaxcyte. Vaxcyte's average media sentiment score of 0.99 beat Ultragenyx Pharmaceutical's score of 0.09 indicating that Vaxcyte is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Ultragenyx Pharmaceutical	6 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral
Vaxcyte	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Ultragenyx Pharmaceutical beats Vaxcyte on 11 of the 16 factors compared between the two stocks.

How does Ultragenyx Pharmaceutical compare to Cytokinetics?

Ultragenyx Pharmaceutical (NASDAQ:RARE) and Cytokinetics (NASDAQ:CYTK) are both mid-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, analyst recommendations, profitability, media sentiment, valuation, institutional ownership, earnings and dividends.

Ultragenyx Pharmaceutical has a beta of 0.39, indicating that its share price is 61% less volatile than the broader market. Comparatively, Cytokinetics has a beta of 0.38, indicating that its share price is 62% less volatile than the broader market.

Ultragenyx Pharmaceutical has a net margin of -91.03% compared to Cytokinetics' net margin of -784.02%. Cytokinetics' return on equity of 0.00% beat Ultragenyx Pharmaceutical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ultragenyx Pharmaceutical	-91.03%	-1,024.42%	-45.78%
Cytokinetics	-784.02%	N/A	-52.86%

Ultragenyx Pharmaceutical has higher revenue and earnings than Cytokinetics. Cytokinetics is trading at a lower price-to-earnings ratio than Ultragenyx Pharmaceutical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ultragenyx Pharmaceutical	$670M	3.79	-$575M	-$6.11	N/A
Cytokinetics	$88.04M	111.14	-$784.96M	-$6.84	N/A

97.7% of Ultragenyx Pharmaceutical shares are owned by institutional investors. 5.2% of Ultragenyx Pharmaceutical shares are owned by insiders. Comparatively, 2.6% of Cytokinetics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Ultragenyx Pharmaceutical currently has a consensus price target of $60.41, suggesting a potential upside of 134.15%. Cytokinetics has a consensus price target of $98.55, suggesting a potential upside of 25.32%. Given Ultragenyx Pharmaceutical's stronger consensus rating and higher possible upside, research analysts clearly believe Ultragenyx Pharmaceutical is more favorable than Cytokinetics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ultragenyx Pharmaceutical	1 Sell rating(s)	2 Hold rating(s)	14 Buy rating(s)	1 Strong Buy rating(s)	2.83
Cytokinetics	1 Sell rating(s)	3 Hold rating(s)	17 Buy rating(s)	1 Strong Buy rating(s)	2.82

In the previous week, Cytokinetics had 9 more articles in the media than Ultragenyx Pharmaceutical. MarketBeat recorded 31 mentions for Cytokinetics and 22 mentions for Ultragenyx Pharmaceutical. Cytokinetics' average media sentiment score of 0.46 beat Ultragenyx Pharmaceutical's score of 0.09 indicating that Cytokinetics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Ultragenyx Pharmaceutical	6 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral
Cytokinetics	6 Very Positive mention(s)	0 Positive mention(s)	14 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Ultragenyx Pharmaceutical beats Cytokinetics on 11 of the 16 factors compared between the two stocks.

How does Ultragenyx Pharmaceutical compare to Krystal Biotech?

Ultragenyx Pharmaceutical (NASDAQ:RARE) and Krystal Biotech (NASDAQ:KRYS) are both mid-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, analyst recommendations, profitability, media sentiment, valuation, institutional ownership, earnings and dividends.

Ultragenyx Pharmaceutical has a beta of 0.39, indicating that its share price is 61% less volatile than the broader market. Comparatively, Krystal Biotech has a beta of 0.5, indicating that its share price is 50% less volatile than the broader market.

Krystal Biotech has a net margin of 53.92% compared to Ultragenyx Pharmaceutical's net margin of -91.03%. Krystal Biotech's return on equity of 19.25% beat Ultragenyx Pharmaceutical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ultragenyx Pharmaceutical	-91.03%	-1,024.42%	-45.78%
Krystal Biotech	53.92%	19.25%	17.62%

Krystal Biotech has lower revenue, but higher earnings than Ultragenyx Pharmaceutical. Ultragenyx Pharmaceutical is trading at a lower price-to-earnings ratio than Krystal Biotech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ultragenyx Pharmaceutical	$670M	3.79	-$575M	-$6.11	N/A
Krystal Biotech	$417.30M	22.34	$204.83M	$7.48	42.29

97.7% of Ultragenyx Pharmaceutical shares are owned by institutional investors. Comparatively, 86.3% of Krystal Biotech shares are owned by institutional investors. 5.2% of Ultragenyx Pharmaceutical shares are owned by insiders. Comparatively, 13.1% of Krystal Biotech shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Ultragenyx Pharmaceutical currently has a consensus price target of $60.41, suggesting a potential upside of 134.15%. Krystal Biotech has a consensus price target of $324.11, suggesting a potential upside of 2.47%. Given Ultragenyx Pharmaceutical's higher possible upside, research analysts clearly believe Ultragenyx Pharmaceutical is more favorable than Krystal Biotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ultragenyx Pharmaceutical	1 Sell rating(s)	2 Hold rating(s)	14 Buy rating(s)	1 Strong Buy rating(s)	2.83
Krystal Biotech	0 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.83

In the previous week, Ultragenyx Pharmaceutical had 11 more articles in the media than Krystal Biotech. MarketBeat recorded 22 mentions for Ultragenyx Pharmaceutical and 11 mentions for Krystal Biotech. Krystal Biotech's average media sentiment score of 0.72 beat Ultragenyx Pharmaceutical's score of 0.09 indicating that Krystal Biotech is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Ultragenyx Pharmaceutical	6 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral
Krystal Biotech	4 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Krystal Biotech beats Ultragenyx Pharmaceutical on 10 of the 16 factors compared between the two stocks.

Get Ultragenyx Pharmaceutical News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding RARE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

RARE vs. The Competition

Export

Metric	Ultragenyx Pharmaceutical	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$2.54B	$3.40B	$6.29B	$12.46B
Dividend Yield	N/A	2.31%	2.79%	5.30%
P/E Ratio	-4.22	18.81	20.87	25.58
Price / Sales	3.79	181.67	521.63	63.56
Price / Cash	N/A	122.51	42.94	55.34
Price / Book	-10.75	6.74	9.86	6.70
Net Income	-$575M	$24.11M	$3.55B	$333.77M
7 Day Performance	-1.26%	0.07%	-0.32%	0.45%
1 Month Performance	5.01%	0.84%	1.34%	4.06%
1 Year Performance	-25.69%	78.10%	41.03%	36.21%

Ultragenyx Pharmaceutical Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
RARE Ultragenyx Pharmaceutical	3.2571 of 5 stars	$25.80 -2.5%	$60.41 +134.2%	-25.3%	$2.54B	$670M	N/A	1,371	Analyst Downgrade Analyst Revision
ABVX Abivax	2.8477 of 5 stars	$117.13 -0.4%	$137.15 +17.1%	+1,918.4%	$9.33B	N/A	N/A	61	Positive News
PRAX Praxis Precision Medicines	3.3976 of 5 stars	$337.61 +4.1%	$590.78 +75.0%	+827.6%	$9.03B	$8.55M	N/A	110	Earnings Report Analyst Forecast Analyst Revision
PCVX Vaxcyte	2.9421 of 5 stars	$58.49 +2.7%	$86.00 +47.0%	+80.5%	$8.22B	N/A	N/A	160	Options Volume
CYTK Cytokinetics	2.8728 of 5 stars	$66.05 +4.3%	$90.55 +37.1%	+152.3%	$7.87B	$88.04M	N/A	250	Trending News Analyst Forecast Insider Trade Options Volume Analyst Revision

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:RARE) was last updated on 5/14/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Ultragenyx Pharmaceutical (RARE) Competitors

RARE vs. ABVX, PRAX, PCVX, CYTK, and KRYS

How does Ultragenyx Pharmaceutical compare to Abivax?

Summary

How does Ultragenyx Pharmaceutical compare to Praxis Precision Medicines?

Summary

How does Ultragenyx Pharmaceutical compare to Vaxcyte?

Summary

How does Ultragenyx Pharmaceutical compare to Cytokinetics?

Summary

How does Ultragenyx Pharmaceutical compare to Krystal Biotech?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

RARE vs. The Competition

Ultragenyx Pharmaceutical Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Ultragenyx Pharmaceutical (RARE) Competitors

RARE vs. ABVX, PRAX, PCVX, CYTK, and KRYS

How does Ultragenyx Pharmaceutical compare to Abivax?

Do institutionals & insiders have more ownership in ABVX or RARE?

Does the media refer more to ABVX or RARE?

Which has more risk & volatility, ABVX or RARE?

Is ABVX or RARE more profitable?

Do analysts rate ABVX or RARE?

Which has stronger valuation and earnings, ABVX or RARE?

Summary

How does Ultragenyx Pharmaceutical compare to Praxis Precision Medicines?

Is RARE or PRAX more profitable?

Do insiders and institutionals hold more shares of RARE or PRAX?

Which has more volatility & risk, RARE or PRAX?

Do analysts recommend RARE or PRAX?

Which has preferable earnings & valuation, RARE or PRAX?

Does the media prefer RARE or PRAX?

Summary

How does Ultragenyx Pharmaceutical compare to Vaxcyte?

Is RARE or PCVX more profitable?

Do insiders and institutionals hold more shares of RARE or PCVX?

Which has more volatility & risk, RARE or PCVX?

Do analysts recommend RARE or PCVX?

Which has preferable earnings & valuation, RARE or PCVX?

Does the media prefer RARE or PCVX?

Summary

How does Ultragenyx Pharmaceutical compare to Cytokinetics?

Which has more volatility and risk, RARE or CYTK?

Is RARE or CYTK more profitable?

Which has better earnings and valuation, RARE or CYTK?

Do institutionals and insiders hold more shares of RARE or CYTK?

Do analysts prefer RARE or CYTK?

Does the media prefer RARE or CYTK?

Summary

How does Ultragenyx Pharmaceutical compare to Krystal Biotech?

Which has more volatility and risk, RARE or KRYS?

Is RARE or KRYS more profitable?

Which has better earnings and valuation, RARE or KRYS?

Do institutionals and insiders hold more shares of RARE or KRYS?

Do analysts prefer RARE or KRYS?

Does the media prefer RARE or KRYS?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

RARE vs. The Competition

Ultragenyx Pharmaceutical Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools